Edition:
India

People: Zynerba Pharmaceuticals Inc (ZYNE.OQ)

ZYNE.OQ on NASDAQ Stock Exchange Global Market

3.75USD
31 Jul 2020
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.75
Open
--
Day's High
--
Day's Low
--
Volume
15
Avg. Vol
333,470
52-wk High
$12.51
52-wk Low
$2.55

Fickenscher, James 

Mr. James E. Fickenscher CPA serves as Chief Financial Officer, Vice President - Corporate Development of the Company. Mr. Fickenscher has more than 30 years of financial, business development and executive leadership experience in the pharmaceutical industry. Prior to joining our company, he served as the senior vice president, chief financial officer of Antares Pharma, Inc., a specialty pharmaceutical company, from November 2014 to September 2016. Previously, Mr. Fickenscher served as chief financial officer of Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, from May 2005 until August 2014. From January 2000 until April 2004, Mr. Fickenscher served as senior vice president chief financial officer of Aventis Behring L.L.C., a wholly owned subsidiary of Aventis, predecessor to Sanofi S.A. Mr. Fickenscher joined Aventis Behring L.L.C. in 1995 as vice president, business development and strategic planning and, from that time until 2000, also held the positions of general manager, Japan and vice president & general manager, Hemophilia Business Unit. Throughout his tenure at Aventis Behring L.L.C, he was also responsible for strategic planning. Prior to Aventis Behring L.L.C, Mr. Fickenscher worked at Rhone-Poulenc Rorer, predecessor to Sanofi S.A., in its Collegeville, PA and Paris, France offices and at Deloitte & Touche LLP. Mr. Fickenscher received his B.S. at Bloomsburg University of Pennsylvania. He is a member of the American Institute of Certified Public Accountants.

Basic Compensation

Total Annual Compensation, USD 390,411
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 433,696
Fiscal Year Total, USD 824,107

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --